Clinical Trials

The Joint Steering Committee oversees a research pipeline that allows for the rapid pivot toward new health threats as they emerge in the Southern Hemisphere landscape. This strategic collaboration between Moderna and CSIRO establishes a robust biosecurity framework intended to fortify Australia’s

The resignation of FDA Commissioner Marty Makary on May 12, 2026, effectively unblocked the administrative queue for scheduling critical drug and device advisory meetings. This shift signals a broader effort to revitalize a system that has long been the backbone of regulatory transparency. The

The significant gender imbalance in multiple sclerosis suggests a sex-microbiota-immune axis that requires specialized analysis to develop effective personalized treatments. The scientific understanding of multiple sclerosis (MS) is currently undergoing a significant paradigm shift. Once viewed

A core-and-spoke staffing model allows growing biotech firms to maintain deep expertise in niche regulatory areas while keeping internal overhead costs manageable. This approach is particularly effective in an era where the line between laboratory innovation and regulatory scrutiny has become

Atrogi intends to launch the next phase of clinical trials in 2027 to establish a definitive proof of concept across a larger and more diverse demographic of patients. For decades, the pharmaceutical industry has searched for a "holy grail" that could fundamentally alter human body composition by

Combining CAR-M with checkpoint inhibitors such as PD-1 blockers creates a multi-pronged therapeutic strategy that addresses the biological complexity of solid tumors more effectively than monotherapy. The landscape of precision medicine is shifting as chimeric antigen receptor technologies evolve